Global Olaparib API Market Research Report 2024

Publication ID:

PB511243670

Publication Date:

November 15, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global Olaparib API market was valued at US$ 928 million in 2023 and is anticipated to reach US$ 2514 million by 2030, witnessing a CAGR of 15.3% during the forecast period 2024-2030.
Olaparib API refers to the active pharmaceutical ingredient (API) in medications containing olaparib, a drug used primarily in cancer treatment. Olaparib is a PARP (poly ADP-ribose polymerase) inhibitor, which works by blocking PARP enzymes involved in DNA repair. This inhibition is particularly effective in cancer cells with BRCA1 or BRCA2 mutations, as these cells rely heavily on PARP for repair. By inhibiting PARP, olaparib causes DNA damage to accumulate in cancer cells, leading to cell death.
North American market for Olaparib API is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Olaparib API is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Olaparib API include ScinoPham Taiwan, Transo-Pharm USA LLC, ALP Pharm Beijing, MSN Laboratories, Alembic Pharmaceuticals, Exelixis, Pfizer, AstraZeneca, Novartis AG, Bayer AG, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Olaparib API, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Olaparib API.
The Olaparib API market size, estimations, and forecasts are provided in terms of sales volume (kg) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Olaparib API market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Olaparib API manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
ScinoPham Taiwan
Transo-Pharm USA LLC
ALP Pharm Beijing
MSN Laboratories
Alembic Pharmaceuticals
Exelixis
Pfizer
AstraZeneca
Novartis AG
Bayer AG
DR. Reddy's Laboratories
Sun Pharmaceutical Industrial
Segment by Type
Ovarian Cancer
Breast Cancer
Pancreatic Cancer
Prostate Cancer
Segment by Application
Pharmaceuticals
Biomedical
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Olaparib API manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Olaparib API in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.鈥�

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Olaparib API Market Overview
1.1 Product Definition
1.2 Olaparib API by Type
1.2.1 Global Olaparib API Market Value Comparison by Type (2024-2030)
1.2.2 Ovarian Cancer
1.2.3 Breast Cancer
1.2.4 Pancreatic Cancer
1.2.5 Prostate Cancer
1.3 Olaparib API by Application
1.3.1 Global Olaparib API Market Value by Application (2024-2030)
1.3.2 Pharmaceuticals
1.3.3 Biomedical
1.3.4 Others
1.4 Global Olaparib API Market Size Estimates and Forecasts
1.4.1 Global Olaparib API Revenue 2019-2030
1.4.2 Global Olaparib API Sales 2019-2030
1.4.3 Global Olaparib API Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Olaparib API Market Competition by Manufacturers
2.1 Global Olaparib API Sales Market Share by Manufacturers (2019-2024)
2.2 Global Olaparib API Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Olaparib API Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Olaparib API, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Olaparib API, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Olaparib API, Product Type & Application
2.7 Global Key Manufacturers of Olaparib API, Date of Enter into This Industry
2.8 Global Olaparib API Market Competitive Situation and Trends
2.8.1 Global Olaparib API Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Olaparib API Players Market Share by Revenue
2.8.3 Global Olaparib API Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Olaparib API Market Scenario by Region
3.1 Global Olaparib API Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Olaparib API Sales by Region: 2019-2030
3.2.1 Global Olaparib API Sales by Region: 2019-2024
3.2.2 Global Olaparib API Sales by Region: 2025-2030
3.3 Global Olaparib API Revenue by Region: 2019-2030
3.3.1 Global Olaparib API Revenue by Region: 2019-2024
3.3.2 Global Olaparib API Revenue by Region: 2025-2030
3.4 North America Olaparib API Market Facts & Figures by Country
3.4.1 North America Olaparib API Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Olaparib API Sales by Country (2019-2030)
3.4.3 North America Olaparib API Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Olaparib API Market Facts & Figures by Country
3.5.1 Europe Olaparib API Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Olaparib API Sales by Country (2019-2030)
3.5.3 Europe Olaparib API Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Olaparib API Market Facts & Figures by Region
3.6.1 Asia Pacific Olaparib API Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Olaparib API Sales by Region (2019-2030)
3.6.3 Asia Pacific Olaparib API Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Olaparib API Market Facts & Figures by Country
3.7.1 Latin America Olaparib API Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Olaparib API Sales by Country (2019-2030)
3.7.3 Latin America Olaparib API Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Olaparib API Market Facts & Figures by Country
3.8.1 Middle East and Africa Olaparib API Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Olaparib API Sales by Country (2019-2030)
3.8.3 Middle East and Africa Olaparib API Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Olaparib API Sales by Type (2019-2030)
4.1.1 Global Olaparib API Sales by Type (2019-2024)
4.1.2 Global Olaparib API Sales by Type (2025-2030)
4.1.3 Global Olaparib API Sales Market Share by Type (2019-2030)
4.2 Global Olaparib API Revenue by Type (2019-2030)
4.2.1 Global Olaparib API Revenue by Type (2019-2024)
4.2.2 Global Olaparib API Revenue by Type (2025-2030)
4.2.3 Global Olaparib API Revenue Market Share by Type (2019-2030)
4.3 Global Olaparib API Price by Type (2019-2030)
5 Segment by Application
5.1 Global Olaparib API Sales by Application (2019-2030)
5.1.1 Global Olaparib API Sales by Application (2019-2024)
5.1.2 Global Olaparib API Sales by Application (2025-2030)
5.1.3 Global Olaparib API Sales Market Share by Application (2019-2030)
5.2 Global Olaparib API Revenue by Application (2019-2030)
5.2.1 Global Olaparib API Revenue by Application (2019-2024)
5.2.2 Global Olaparib API Revenue by Application (2025-2030)
5.2.3 Global Olaparib API Revenue Market Share by Application (2019-2030)
5.3 Global Olaparib API Price by Application (2019-2030)
6 Key Companies Profiled
6.1 ScinoPham Taiwan
6.1.1 ScinoPham Taiwan Company Information
6.1.2 ScinoPham Taiwan Description and Business Overview
6.1.3 ScinoPham Taiwan Olaparib API Sales, Revenue and Gross Margin (2019-2024)
6.1.4 ScinoPham Taiwan Olaparib API Product Portfolio
6.1.5 ScinoPham Taiwan Recent Developments/Updates
6.2 Transo-Pharm USA LLC
6.2.1 Transo-Pharm USA LLC Company Information
6.2.2 Transo-Pharm USA LLC Description and Business Overview
6.2.3 Transo-Pharm USA LLC Olaparib API Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Transo-Pharm USA LLC Olaparib API Product Portfolio
6.2.5 Transo-Pharm USA LLC Recent Developments/Updates
6.3 ALP Pharm Beijing
6.3.1 ALP Pharm Beijing Company Information
6.3.2 ALP Pharm Beijing Description and Business Overview
6.3.3 ALP Pharm Beijing Olaparib API Sales, Revenue and Gross Margin (2019-2024)
6.3.4 ALP Pharm Beijing Olaparib API Product Portfolio
6.3.5 ALP Pharm Beijing Recent Developments/Updates
6.4 MSN Laboratories
6.4.1 MSN Laboratories Company Information
6.4.2 MSN Laboratories Description and Business Overview
6.4.3 MSN Laboratories Olaparib API Sales, Revenue and Gross Margin (2019-2024)
6.4.4 MSN Laboratories Olaparib API Product Portfolio
6.4.5 MSN Laboratories Recent Developments/Updates
6.5 Alembic Pharmaceuticals
6.5.1 Alembic Pharmaceuticals Company Information
6.5.2 Alembic Pharmaceuticals Description and Business Overview
6.5.3 Alembic Pharmaceuticals Olaparib API Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Alembic Pharmaceuticals Olaparib API Product Portfolio
6.5.5 Alembic Pharmaceuticals Recent Developments/Updates
6.6 Exelixis
6.6.1 Exelixis Company Information
6.6.2 Exelixis Description and Business Overview
6.6.3 Exelixis Olaparib API Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Exelixis Olaparib API Product Portfolio
6.6.5 Exelixis Recent Developments/Updates
6.7 Pfizer
6.7.1 Pfizer Company Information
6.7.2 Pfizer Description and Business Overview
6.7.3 Pfizer Olaparib API Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Pfizer Olaparib API Product Portfolio
6.7.5 Pfizer Recent Developments/Updates
6.8 AstraZeneca
6.8.1 AstraZeneca Company Information
6.8.2 AstraZeneca Description and Business Overview
6.8.3 AstraZeneca Olaparib API Sales, Revenue and Gross Margin (2019-2024)
6.8.4 AstraZeneca Olaparib API Product Portfolio
6.8.5 AstraZeneca Recent Developments/Updates
6.9 Novartis AG
6.9.1 Novartis AG Company Information
6.9.2 Novartis AG Description and Business Overview
6.9.3 Novartis AG Olaparib API Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Novartis AG Olaparib API Product Portfolio
6.9.5 Novartis AG Recent Developments/Updates
6.10 Bayer AG
6.10.1 Bayer AG Company Information
6.10.2 Bayer AG Description and Business Overview
6.10.3 Bayer AG Olaparib API Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Bayer AG Olaparib API Product Portfolio
6.10.5 Bayer AG Recent Developments/Updates
6.11 DR. Reddy's Laboratories
6.11.1 DR. Reddy's Laboratories Company Information
6.11.2 DR. Reddy's Laboratories Description and Business Overview
6.11.3 DR. Reddy's Laboratories Olaparib API Sales, Revenue and Gross Margin (2019-2024)
6.11.4 DR. Reddy's Laboratories Olaparib API Product Portfolio
6.11.5 DR. Reddy's Laboratories Recent Developments/Updates
6.12 Sun Pharmaceutical Industrial
6.12.1 Sun Pharmaceutical Industrial Company Information
6.12.2 Sun Pharmaceutical Industrial Description and Business Overview
6.12.3 Sun Pharmaceutical Industrial Olaparib API Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Sun Pharmaceutical Industrial Olaparib API Product Portfolio
6.12.5 Sun Pharmaceutical Industrial Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Olaparib API Industry Chain Analysis
7.2 Olaparib API Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Olaparib API Production Mode & Process
7.4 Olaparib API Sales and Marketing
7.4.1 Olaparib API Sales Channels
7.4.2 Olaparib API Distributors
7.5 Olaparib API Customers
8 Olaparib API Market Dynamics
8.1 Olaparib API Industry Trends
8.2 Olaparib API Market Drivers
8.3 Olaparib API Market Challenges
8.4 Olaparib API Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

ScinoPham Taiwan
Transo-Pharm USA LLC
ALP Pharm Beijing
MSN Laboratories
Alembic Pharmaceuticals
Exelixis
Pfizer
AstraZeneca
Novartis AG
Bayer AG
DR. Reddy's Laboratories
Sun Pharmaceutical Industrial

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂